Navigation Links
Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
Date:5/6/2008

SCOTTSDALE, Ariz., May 6 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets products that provide consumers with "Better Ways to Get Better(R)," announced today that financial results for the fiscal fourth quarter and year ended March 31, 2008 will be released after the market closes on Monday, May 12, 2008. An earnings conference call will be held the following morning on Tuesday, May 13, 2008 at 11:00 AM ET.

To access the teleconference, please call (877) 863-5191 (domestic) or (706) 643-6826 (international), access number 46849571. To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on the fourth quarter fiscal 2008 teleconference icon.

A replay of the call will be available at (800) 642-1687 (domestic) or (706) 645-9291 (international), access number 46849571 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development, manufacture and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells Zicam(R) and Nasal Comfort(TM) products in the cough and cold category. The Company's flagship product, Zicam Cold Remedy nasal gel, is a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); Zicam Cold Remedy RapidMelts(TM); Zicam Allergy Relief; Zicam Cold Remedy Swabs(TM); Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to http://www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at http://www.matrixxinc.com. For additional information, contact William Hemelt, Chief Financial Officer, 602-385-8888, or Bill Barba, Treasurer, at 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.


'/>"/>
SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
4. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
5. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
6. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
9. Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program
10. Congress Debates Policy Discussion to Be Streamed Live on NextGenWeb.org
11. Inforum Presents Panel Discussion on The Future of the U.S. Health Care System: What It Will Cost in Dollars and Quality of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... ... Outdoor Adventure”: a turtle’s backyard adventure that teaches the importance of obeying the rules. ... and mother to three amazing, and supportive, children. Paula lives in her native ... loves to tell stories to her children, play board games, bake, and read lots ...
(Date:7/22/2017)... , ... July 22, 2017 , ... ... with irreparable rotator cuff repairs the opportunity to return to sports and jobs ... American Orthopaedic Society for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. ...
(Date:7/21/2017)... ... ... The Ellis Agency, an eastern Georgie provider of insurance management and financial ... event with the goal of bringing in support for epilepsy patients in the greater ... recently launched a charity campaign of her own by donating her birthday to the ...
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today ... eco-friendly odor-control solution for colleges and universities at the APPA 2017 Annual ... severe cannabis and tobacco smoke odors without the use of harsh chemicals, Fresh Wave ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: